Fed Circ written description ruling overturns $1.2 billion award

Kite Pharma has successfully persuaded the US Court of Appeals for the Federal Circuit to reverse a $1.2 billion win for the Bristol-Meyer s Squibb owned Juno Therapeutics over a cancer treatment patent.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic

25 February 2021 A panel of the US Court of Appeals for the Federal Circuit has considered for a second time the $235 million award to GlaxoSmithKline after Teva Pharmaceuticals was found to have infringed its Coreg heart drug.

Americas

Cochlear's $268m damages bill stands, says Fed Circuit

20 May 2020 Australian ear implants manufacturer Cochlear must pay $268 million for infringing a patent owned by a US medical research organisation.

Big Pharma

BMS petitions SCOTUS to revive $1.2bn win

16 June 2022 BMS unit Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have urged the US Supreme Court to reinstate their $1.2 billion win in a patent clash with Kite Pharma, a subsidiary of Gilead.